CompletedPhase 1NCT01062152
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Telik
- Principal Investigator
- Gail Brown, M.D.Telik
- Intervention
- Ezatiostat Hydrochloride(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2013
Study locations (9)
- Mayo Clinic, Phoenix, Arizona, United States
- Loyola University Chicago Cardinal Benardin Cancer Center, Maywood, Illinois, United States
- Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Columbia University Medical Center, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- MDAnderson, Houston, Texas, United States
- Cancer Care Centers of South Texas, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01062152 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.